Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camizestrant in Early-Stage Estrogen Receptor-Positive Endometrial Cancer
NCT07840443Phase 2Not yet recruiting
- Sponsor
- University Health Network
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of camizestrant in endometrial cancer (EC), sponsored by University Health Network. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
camizestrant
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07840443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840443.